LEQSELVI two-year data in severe alopecia areata shows sustained efficacy at EADV Congress 2026

Sun Pharma said LEQSELVI (deuroxolitinib) features in seven presentations at EADV Congress 2026, including a featured oral presentation on up to two years of long-term safety data.

Thu 1 Oct 2026

Week-108 response maintenance

93.9% of Week-52 responders maintained response at Week 108

Nonresponder response by Week 52

76.6% of baseline nonresponders achieved response by Week 52

FDA-approved dose

8 mg twice-daily dose

Safety findings

no deaths, thrombosis or major adverse cardiovascular events were reported

EADV Congress 2026 presentations

LEQSELVI features in seven presentations; one of 22 Sun Pharma presentations in dermatology and immunology

Sun Pharmaceutical Industries announced that LEQSELVI (deuroxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including one featured oral presentation.

The featured oral presentation

• Reported long-term safety results from a European open-label extension (OLE) study evaluating up to two years of treatment in adults with severe alopecia areata.
• Found the safety profile of LEQSELVI remained generally consistent with previous clinical experience through up to two years of open-label treatment.
• Most treatment-emergent adverse events were mild or moderate in severity, treatment discontinuations due to adverse events were uncommon, and no deaths, thrombosis or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice daily.

Durability of hair regrowth

• Long-term efficacy analyses presented in a poster showed durable scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European OLE.
• Of OLE baseline treatment responders (SALT score 20 or less) maintaining response at Week 52 and continuing in the study, 93.9% maintained response at Week 108.
• Many patients (76.6%) who were baseline nonresponders (SALT score above 20) achieved response by Week 52; at Week 52, only responders continued in the study, and of these, 96.8% maintained that response at Week 108.
• A Severity of Alopecia Tool (SALT) score of 100 represents total scalp hair loss, whereas a score of 0 represents no scalp hair loss.

Wider data set shared at the congress

• Additional presentations of pooled post hoc analyses of THRIVE-AA1 and THRIVE-AA2 showed consistent efficacy across clinically relevant patient subgroups, including patients with baseline eyebrow, eyelash or nail involvement, and those with both shorter- and longer-duration disease episodes.
• The LEQSELVI data presentation is one of 22 presentations from Sun Pharma across its dermatology and immunology portfolio.

About the product

• LEQSELVI (deuroxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2, FDA-approved for the treatment of adults with severe alopecia areata.
• Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, causing partial or complete hair loss on the scalp and body, and may affect up to 2.5% of the United States and global population during their lifetime.
• Sun Pharma's Innovative Medicines portfolio spans dermatology, ophthalmology and onco-dermatology and accounts for about 20% of company sales.

How to read this

• The update is a scientific and medical communication about long-term data for an already FDA-approved product.
• The company's own commentary focuses on long-term tolerability, durability of response and maintenance of clinical benefit, which it says supports use as a long-term treatment option for eligible adults.
• For investors tracking the company's innovative medicines franchise, this adds to the body of evidence around one of its dermatology products, alongside the safety information the company has published with the release.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.